| Item Type | Name |
|
Concept
|
Enzyme Inhibitors
|
|
Concept
|
Protease Inhibitors
|
|
Concept
|
Angiogenesis Inhibitors
|
|
Concept
|
Topoisomerase I Inhibitors
|
|
Concept
|
Nucleic Acid Synthesis Inhibitors
|
|
Concept
|
Histone Deacetylase Inhibitors
|
|
Concept
|
Protein Kinase Inhibitors
|
|
Academic Article
|
Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
|
|
Academic Article
|
Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer.
|
|
Academic Article
|
New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents.
|
|
Academic Article
|
Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
|
|
Academic Article
|
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time.
|
|
Academic Article
|
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
|
|
Academic Article
|
Protein kinase C beta in malignant pleural mesothelioma.
|
|
Academic Article
|
Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor.
|
|
Academic Article
|
Antiangiogenic therapies for mesothelioma.
|
|
Academic Article
|
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.
|
|
Academic Article
|
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
|
|
Academic Article
|
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
|
|
Academic Article
|
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report.
|
|
Academic Article
|
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.
|
|
Academic Article
|
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
|
|
Academic Article
|
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.
|
|
Academic Article
|
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.
|
|
Academic Article
|
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.
|
|
Academic Article
|
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
|
|
Academic Article
|
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
|
|
Academic Article
|
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.
|
|
Academic Article
|
Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance).
|
|
Academic Article
|
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
|
|
Academic Article
|
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
|
|
Concept
|
Poly(ADP-ribose) Polymerase Inhibitors
|
|
Concept
|
Proteasome Inhibitors
|
|
Grant
|
Novel Targeted Therapy in Pancreatic Cancer
|